FALCPA allergen labeling requires US food brands to declare nine major allergens — milk, eggs, fish, crustacean shellfish, tree nuts, peanuts, wheat, soybeans, and sesame — on FDA-regulated packaged foods, either parenthetically inside the ingredient list or in a properly formatted “Contains” statement adjacent to it. This guide covers the mandatory label elements, correct “Contains” formatting, where voluntary precautionary statements fit, and how in-house variable-data printing keeps labels current as products and regulations change.
Practical compliance reference only — not legal or regulatory advice. Verify all requirements against current FDA regulations and consult qualified regulatory counsel before implementing label changes.
FALCPA was enacted in 2004, effective January 1, 2006 — establishing a federal mandate for clear allergen disclosure on all FDA-regulated packaged food labels.
The Food Allergen Labeling and Consumer Protection Act of 2004 (FALCPA) governs how major food allergens must be disclosed on packaged foods regulated by the FDA under the Federal Food, Drug, and Cosmetic Act. It applies to most packaged foods sold in the United States, including dietary supplements, but does not cover meat, poultry, or most egg products that fall under USDA food label guidelines administered by FSIS.
Under FALCPA, any ingredient that is or contains protein from a major food allergen must be declared on the label using the plain English (common or usual) name of the allergen source. FDA permits two acceptable declaration methods:
Parenthetical declaration within the ingredient list
The allergen source name is included directly in the ingredient list, either as part of the ingredient name or in a parenthetical immediately following it. Example: “lecithin (soy), whey (milk).” No separate statement is required if all allergens are covered this way.
Separate “Contains” statement
A standalone statement placed immediately after or adjacent to the ingredient list, listing all major allergens present. Either method satisfies the statute, but the chosen approach must be applied consistently and the allergen source name must be unambiguous.
Type size and legibility requirements
Declarations must appear in type at least as prominent as the surrounding ingredient text and must be legible to a typical consumer under normal use. FDA does not specify a fixed point size; the practical expectation is parity with the ingredient declaration.
Who bears compliance responsibility
The manufacturer, packer, or distributor whose name appears on the label is accountable. Co-manufacturers, private label brands, and contract manufacturing partners share responsibility based on their agreements — but the entity on the label faces FDA enforcement exposure.
Eight allergens were defined in the original 2004 FALCPA legislation. The FASTER Act added sesame as the ninth, with mandatory compliance effective January 1, 2023.
Allergen declaration is one component of a broader set of food traceability and labeling requirements food brands must manage. The table below lists all nine allergens currently recognized under FDA regulations, with required declaration name format, species/variety disclosure rules, and the legislation that established each.
Allergen | Required Disclosure Name | Species / Variety Detail Required? | Law / Effective Date |
Milk | “milk” | No | FALCPA / Jan 1, 2006 |
Eggs | “egg” | No | FALCPA / Jan 1, 2006 |
Fish | “fish” + species, e.g., “fish (salmon)” | Yes — species name required | FALCPA / Jan 1, 2006 |
Crustacean shellfish | “shellfish” + species, e.g., “shellfish (shrimp)” | Yes — species name required | FALCPA / Jan 1, 2006 |
Tree nuts | “tree nuts” + variety, e.g., “tree nuts (almond)” | Yes — specific nut variety required | FALCPA / Jan 1, 2006 |
Peanuts | “peanut” | No | FALCPA / Jan 1, 2006 |
Wheat | “wheat” | No | FALCPA / Jan 1, 2006 |
Soybeans | “soy” or “soybean” | No | FALCPA / Jan 1, 2006 |
Sesame | “sesame” | No | FASTER Act / Jan 1, 2023 |
Common compliance errors include declaring “nuts” generically, omitting the species for fish or shellfish, treating coconut inconsistently (FDA classifies coconut as a tree nut for allergen labeling purposes), and failing to update legacy label inventory for sesame following the FASTER Act. Brands that printed large label runs before the January 1, 2023 effective date have had to redesign, overprint, or write off stock that no longer reflects current compliance requirements.
A “Contains” statement must be complete, use common allergen names, and appear immediately after or adjacent to the ingredient list — partial statements are not FALCPA-compliant.
When a brand uses the “Contains” statement approach — alone or alongside parenthetical declarations — FDA expects a specific structure:
Capitalization and punctuation
The word “Contains” must begin with a capital “C,” followed by the names of the allergen sources present, typically separated by commas, with a period closing the list. Example: Contains: Milk, Wheat, Soy, Almond.
Placement on the label
The statement must appear immediately after or adjacent to the ingredient list, on the same label panel, with no intervening unrelated text. FDA treats proximity to the ingredient list as a non-negotiable formatting requirement.
Type size
The “Contains” statement must be set in type no smaller than the ingredient list. FDA does not mandate a minimum point size, but conspicuousness relative to the ingredient declaration is the standard.
Completeness
If a “Contains” statement is used, it must list every major allergen present in the product. A partial statement that covers, say, milk and wheat but omits sesame does not satisfy FALCPA for the omitted allergen — even if sesame appears in the ingredient list by common name.
When “Contains” and parenthetical declarations are used together
Many brands include both a parenthetical and a “Contains” statement for clarity and to meet retailer requirements. When both are used, they must be consistent — an allergen cannot appear in one declaration method but be absent from the other.
Multi-variety tree nuts and fish species
For products containing multiple tree nut varieties or fish species, each must be listed by specific name in the “Contains” statement. “Contains: Tree Nuts” without specifying almond, cashew, etc. is not sufficient.
Both methods satisfy FALCPA — the right choice depends on label panel space, SKU allergen complexity, and retailer requirements.
Element | Parenthetical in Ingredient List | “Contains” Statement |
Placement | Inside the ingredient declaration, immediately after the ingredient name | Immediately after or adjacent to the ingredient list — same panel, no intervening text |
Type size | Same as surrounding ingredient text | No smaller than the ingredient list type |
Must cover all 9 allergens present | Yes — all allergens in the product must be declared | Yes, if used — partial “Contains” statements are not compliant |
Required by FALCPA? | Required when a “Contains” statement is not used | Optional — but must be complete and correctly formatted if included |
Common use case | Single-panel SKUs, products with minimal allergen load, clean-label formats | High-allergen products, retailer-driven label specifications, consumer-facing clarity |
Can both methods be used together? | Yes — many brands use both. When both are used, they must be mutually consistent. | |
Precautionary allergen statements are voluntary, unregulated by FDA as mandatory declarations, and cannot substitute for required FALCPA disclosure or for cGMP controls.
Voluntary precautionary statements — also called precautionary allergen labeling (PAL) — address cross-contact risk from shared equipment, production lines, or manufacturing facilities. Common formats include “May contain traces of peanuts” or “Manufactured in a facility that also processes wheat.”
FDA’s position is clear: precautionary statements are voluntary and do not substitute for current Good Manufacturing Practices (cGMPs). They cannot be used to mask inadequate sanitation, poor allergen segregation, or weak supplier controls, and they must not be false or misleading to consumers.
When precautionary statements are appropriate
Precautionary language should be based on a documented risk assessment of actual cross-contact exposure — not applied as a blanket disclaimer. Using “May Contain” across every product without a supporting risk assessment is considered misleading by FDA and erodes consumer trust with the allergen-sensitive population most dependent on accurate labeling.
Cross-contact vs. cross-contamination
Cross-contact is the preferred technical and regulatory term for the unintended transfer of allergen residues between products. Cross-contamination refers broadly to microbial or chemical hazards. Using “cross-contact” specifically for allergen events matters in regulatory correspondence, FSMA documentation, and food safety audits.
What precautionary statements cannot do
A precautionary statement cannot substitute for a mandatory FALCPA allergen declaration. If milk is a known ingredient in a product, “May Contain Milk” does not satisfy FALCPA — the milk must be declared as an ingredient allergen source. This is a common error when brands reformulate quickly or launch new SKUs under time pressure.
Change-control and precautionary statement drift
Precautionary statement drift — where advisory language expands to cover allergens not supported by a current risk assessment, or fails to reflect line or supplier changes — is often a leading indicator of weak change-control discipline. Locking the precautionary language to a controlled, SKU-level master record with mandatory review triggers helps prevent the inconsistencies that confuse consumers and create audit exposure.
The operational challenge of allergen labeling compliance is not understanding the rules — it is keeping labels current as the business and regulations change.
Reformulations, supplier swaps, new SKU variants, private-label runs, and regulatory updates like the FASTER Act sesame mandate all trigger label revisions. When labels come from external converters with long lead times and high minimum order quantities, brands face a compounding problem: each change event forces a choice between writing off non-compliant pre-printed label inventory or running the risk of shipping product with outdated allergen declarations.
In-house digital label printers change that equation. On-demand variable data printing allows brands to produce exactly the quantity of each allergen-variant label needed for a given run, switching between label versions through artwork changes in the RIP software — with zero plate changeover and zero setup waste.
The risk of carrying short-run food label printing non-compliant stock through a regulatory change is one of the strongest operational arguments for on-demand production over batch-ordering inventory months in advance.
The ArrowJet Aqua 330R is Arrow Systems’ high-resolution aqueous inkjet label press, used in food and beverage production environments for exactly this type of allergen-variant label management. For allergen labeling specifically, this enables:
The operational benefit extends beyond speed. Treating the label as a controlled, current document — rather than a fixed inventory item — is particularly valuable for brands managing many SKUs, frequent new-product development, or contract-manufactured lines where allergen profiles vary across the portfolio.
Brands moving allergen label production in-house typically pair the press with a governed artwork workflow: regulatory approval, version lock, and audit trail before any print job releases. That combination is where compliance and production operations reinforce each other.
Specification | ArrowJet Aqua 330R |
Print speed | Up to 195 ft/min (60 m/min) |
Print resolution | 1600 × 1600 dpi |
Max print width | 12.75″ (324 mm) |
Ink system | CMYK aqueous pigment — Nestle Guidance compliant; REACh and RoHS 3 compliant |
Print engine | Memjet DuraFlex™ |
Substrates supported | Coated paper, BOPP, PP, PET, PVC, Mylar, Tyvek, and more |
Artwork changeover | Digital via RIP software — no plates required |
Common questions from QA, regulatory, and packaging operations teams on FALCPA scope, sesame compliance, and enforcement consequences.
No. FALCPA applies to FDA-regulated foods under the Federal Food, Drug, and Cosmetic Act. Meat, poultry, and processed egg products fall under USDA’s Food Safety and Inspection Service (FSIS), which administers its own allergen labeling requirements separately. In practice, FSIS allergen labeling expectations closely mirror FALCPA, but they are governed by different regulatory authority and enforced through different mechanisms.
The “Contains” statement is optional if all major allergens are properly disclosed via parenthetical declarations within the ingredient list. However, if a “Contains” statement is used, it must list every major allergen present in the product, appear immediately after or adjacent to the ingredient list, and be set in type no smaller than the ingredient list. Partial “Contains” statements are not compliant — if the statement is used, it must be complete.
Since January 1, 2023, sesame must be declared as a major allergen when present in FDA-regulated packaged foods. Labels printed before that date that do not declare sesame are no longer compliant for products manufactured after the effective date. Brands have generally addressed this by reprinting, overprinting, or transitioning to on-demand digital label production — which allows allergen declaration updates without carrying large non-compliant pre-printed label stock through a regulatory change.
No. Voluntary precautionary statements are not required by FALCPA or FDA. They are advisory and must not replace cGMP controls for allergen cross-contact. When used, they should reflect a documented risk assessment — not serve as a blanket disclaimer for inadequate allergen segregation practices. Overuse of precautionary statements on products without a genuine evaluated cross-contact risk is considered misleading.
Consequences can include FDA warning letters, product detention, mandatory or voluntary recalls, retailer chargebacks, and litigation exposure. Undeclared allergens are consistently among the leading causes of Class I food recalls in the United States — the highest-severity recall classification, reflecting a reasonable probability of serious adverse health consequences. A single undeclared allergen event can generate significant financial, reputational, and regulatory damage for the brand responsible.
If your team is managing FALCPA compliance across a growing SKU portfolio, frequent formulation changes, or contract-manufactured lines with variable allergen profiles, an in-house labeling assessment can quantify where variable-data digital printing fits in your workflow. Book a 20-minute allergen labeling audit with Arrow Systems to review your current SKU portfolio, compliance profile, and allergen label production environment.
Table of Contents Cannabis Label Versioning Workflow for Multi-State Brands A cannabis label versioning workflow produces state-specific labels from one master template by moving state-variable
Table of Contents Water-Based vs UV-Cured Label Adhesive: Food & Pharma Guide Water-based adhesives suit dry, ambient containers; UV-cured hot melts suit cold, wet, curved
Table of Contents Is Your Confectionery Brand Ready to Bring Flexible Packaging In-House? In-house flexible packaging pays off for confectionery brands with many SKUs, short
Table of Contents Label Slitting and Matrix Removal: Where Converters Lose Finishing Time Label slitting and matrix removal, plus rewinding, cost converters more finishing time
Table of Contents Limited Edition Spirits Label Printing: 4 Holiday Delay Fixes Limited edition spirits label printing runs late because of the calendar, not the
Table of Contents Section 179 Label Printer Timing: Install Before December 31 A section 179 label printer purchase counts for 2026 only if the press